LGND

Ligand Pharmaceuticals Inc

311.13

Nov 13 • 1:11 PM ET -5.14 (-1.63%)

Healthcare Biotechnology USA Mid NASD

Peers: RPRX HALO INVA OABI ABCL IONS ARWR PTCT EXEL ANIP

| Held by: IJR VTI IWM VB VXF XSMO IWO SPSM IJT VBR

Scroll to Statements

Index	RUT
Market Cap	6.22B
Enterprise Value	6.93B
Income	51.46M
Sales	253.83M
Book/sh	48.09
Cash/sh	22.57
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	Jul 02, 2010
Dividend Gr. 3/5Y	- -
Payout	0.00%
Employees	47
IPO	Nov 18, 1992

P/E	138.78
Forward P/E	26.03
PEG	1.30
P/S	24.52
P/B	6.47
P/C	13.78
P/FCF	68.67
EV/EBITDA	94.26
EV/Sales	27.29
Quick Ratio	1.19
Current Ratio	1.22
Debt/Eq	1.20
LT Debt/Eq	0.73
Option/Short	Yes / Yes

EPS (ttm)	2.24
EPS next Y	11.95
EPS next Q	2.88
EPS this Y	17.85%
EPS next Y	24.77%
EPS next 5Y	20.09%
EPS past 3/5Y	- -
Sales past 3/5Y	10.96% 7.54%
EPS Y/Y TTM	8.35%
Sales Y/Y TTM	1.03%
EPS Q/Q	-125.10%
Sales Q/Q	-31.80%
Earnings	Oct 29 BMO
EPS/Sales Surpr.	14.66% 2.26%

Insider Own	2.42%
Insider Trans	-16.56%
Inst Own	113.56%
Inst Trans	9.55%
ROA	2.77%
ROE	5.38%
ROIC	3.09%
Gross Margin	81.63%
Oper. Margin	14.38%
Profit Margin	20.27%
SMA20	-0.01%
SMA50	3.11%
SMA200	20.41%
Trades

Shs Outstand	20.00M
Shs Float	19.52M
Short Float	12.62%
Short Ratio	10.87
Short Interest	2.46M
52W High	326.63 -4.75%
52W Low	175.89 76.89%
Volatility	3.55% 3.66%
ATR (14)	11.31
RSI (14)	51.72
Beta	1.21
Rel Volume	0.37
Avg Volume	226.71K
Volume	49,320

Perf Week	1.61%
Perf Month	4.23%
Perf Quarter	6.64%
Perf Half Y	45.93%
Perf YTD	64.56%
Perf Year	54.58%
Perf 3Y	463.95%
Perf 5Y	198.72%
Perf 10Y	351.25%
Recom	1.09
Target Price	361.27
Prev Close	316.27
Price	311.13
Change %	-1.63%

Consensus

Strong Buy

Avg. Price Target

$361.27

Implied Upside

+16.1%

Analysts13incl. previous ratings

Rating Distribution11 Buy · 2 Hold · 0 Sell

Date	Action	Analyst	Rating Change	Price Target Change	Implied Upside
Sep 25, 2026	Initiated	BBarclays	Overweight	$345	+10.9%
Aug 14, 2026	Initiated	LLeerink Partners	Outperform
Jul 21, 2026	Resumed	CCitigroup	Buy	$387	+24.4%
Mar 11, 2026	Initiated	BBofA Securities	Buy	$244	-21.6%
Dec 09, 2025	Initiated	CCitigroup	Buy	$270	-13.2%
Apr 10, 2025	Initiated	SStifel	Buy	$143	-54.0%
Oct 03, 2024	Initiated	OOppenheimer	Outperform	$135	-56.6%
Jul 30, 2024	Initiated	RRBC Capital Mkts	Outperform	$130	-58.2%
Apr 14, 2021	Resumed	SStephens	Overweight	$200	-35.7%
Feb 04, 2021	Reiterated	HH.C. Wainwright	Buy	$229 → $310	-0.4%
Oct 06, 2020	Initiated	BBarclays	Overweight	$156	-49.9%
Mar 24, 2020	Downgrade	AArgus	Buy → Hold
Mar 10, 2020	Initiated	GGuggenheim	Neutral
Feb 06, 2020	Initiated	TThe Benchmark Company	Buy	$135	-56.6%
Sep 19, 2019	Upgrade	BBarclays	Equal Weight → Overweight	$110 → $132	-57.6%
Jun 11, 2019	Initiated	BBarclays	Equal Weight	$131	-57.9%
May 03, 2019	Reiterated	HH.C. Wainwright	Buy	$254 → $214	-31.2%
Mar 06, 2019	Reiterated	HH.C. Wainwright	Buy	$281 → $254	-18.4%
Oct 29, 2018	Upgrade	RROTH Capital	Neutral → Buy
Oct 02, 2018	Reiterated	HH.C. Wainwright	Buy	$270 → $280	-10.0%

Oct-29-26 11:21AM	Ligand's Royalty Engine Drives A Clean EPS Beat And Second Guidance Raise, But Held Revenue Outlook And A Heavier Balance Sheet Temper The Story (Earnings Whispers)
07:20AM	Ligand: Q3 Earnings Snapshot (Associated Press)
07:00AM	Ligand Reports Third Quarter 2026 Financial Results (GlobeNewswire)
Oct-27-26 04:01PM	Ligand to Participate in November Investor Conferences (GlobeNewswire)
Oct-22-26 04:01PM	Ligand to Host Investor Day on December 8, 2026 (GlobeNewswire)
01:14PM	Loading…
Oct-21-26 01:14PM	Ligand's First Clean Look At Zoma Tests A Raised Profit Floor Wall Street Hasn't Matched (Earnings Whispers)
Oct-15-26 07:00AM	Ligand to Report Third Quarter 2026 Financial Results on October 29, 2026 (GlobeNewswire)
Sep-25-26 09:43AM	Twilio downgraded, Synopsys upgraded: Wall Street's top analyst calls (The Fly)
Sep-24-26 07:00AM	Ligand and AvenCell Therapeutics Enter Financing Agreement to Advance Pipeline of Next-Generation CAR-T Therapies for Up to $47 Million (GlobeNewswire)
Sep-22-26 09:00AM	Primrose Bio Raises Significant Growth Capital Investment Led by Signet Healthcare Partners (PR Newswire)
07:00AM	Ligand Acquires Royalty and Milestone Interest in Santen's Ryjunea from Sydnexis for $23 Million (GlobeNewswire)
Aug-26-26 07:00AM	Ligand to Participate in September Investor Conferences (GlobeNewswire)
Aug-06-26 07:18PM	Ligand Pharmaceuticals Inc (LGND) (Q2 2026) Earnings Call Highlights: Royalty Revenue Surges ... (GuruFocus.com)
07:24AM	Ligand: Q2 Earnings Snapshot (Associated Press)
07:00AM	Ligand Reports Second Quarter 2026 Financial Results (GlobeNewswire)
02:15PM	Loading…
Jul-27-26 02:15PM	This Stock Of The Day Rides Big Pharma Royalties; It's Up 56% In 2026 (Investor's Business Daily)
Jul-23-26 07:00AM	Ligand to Report Second Quarter 2026 Financial Results on August 6, 2026 (GlobeNewswire)
Jul-21-26 09:40AM	Shopify downgraded, Five Below upgraded: Wall Street's top analyst calls (The Fly)
Jul-14-26 09:00AM	Ligand Completes Acquisition of XOMA Royalty, Creating a Portfolio of More than 200 Biopharmaceutical Royalty Assets (GlobeNewswire)
Jul-13-26 12:53PM	Agenus shares surge as company secures up to $340M to advance colon cancer trial (Proactive)
08:25AM	Agenus Shares Rise After Securing Up to $340 Million Financing Package (AGEN) (InvestorsHub)
Jun-25-26 04:01PM	Ligand Announces Closing of Convertible Senior Notes Offering (GlobeNewswire)
Jun-23-26 04:00AM	Ligand Announces Pricing of Upsized $625 Million Convertible Senior Notes Offering (GlobeNewswire) +6.59%
Jun-22-26 07:00AM	Ligand Announces Proposed Offering of $550 Million of Convertible Senior Notes Due 2031 (GlobeNewswire)
Jun-10-26 07:00AM	Ligand Announces 2026 Investor Day in New York City (GlobeNewswire)
May-27-26 04:01PM	Ligand to Participate in June Investor Conferences (GlobeNewswire)
May-07-26 07:28AM	Ligand: Q1 Earnings Snapshot (Associated Press) -9.55%
07:00AM	Ligand Reports First Quarter 2026 Financial Results (GlobeNewswire)
May-05-26 04:01PM	Ligand to Participate in May Investor Conferences (GlobeNewswire)
Apr-27-26 10:19AM	Royalty Powerhouse: Ligand And Xoma Unite In $739 Million Deal (Investor's Business Daily)
09:10AM	Loading…
09:10AM	Ligand Pharmaceuticals buying Xoma Royalty for $739 million (Quartz)
07:00AM	Ligand to Acquire XOMA Royalty, Further Accelerating Profit Growth and Strengthening Ligand's Position as a Leading Biopharma Royalty Aggregator (GlobeNewswire)
06:00AM	Ligand Pharmaceuticals Is Buying Xoma for Nearly $740 Million (The Wall Street Journal)
Apr-22-26 07:00AM	Ligand to Report First Quarter 2026 Financial Results on May 7, 2026 (GlobeNewswire)
Apr-14-26 07:00AM	Ligand Partner Travere Therapeutics Receives Full FDA Approval for FILSPARI (sparsentan) in FSGS (GlobeNewswire) +8.85%
Mar-26-26 07:00AM	Ligand Advances Strategic Growth with Expanded and Strengthened Business Development Team (GlobeNewswire)
Mar-12-26 04:25PM	How A Broad Sell-Off Rattled Top 3% Breakout Stock Ligand Pharma (Investor's Business Daily)
Mar-11-26 01:49PM	Ligand Pharmaceuticals offers high-margin exposure to biopharma growth, BofA says (Proactive)
09:40AM	Oracle, Nike upgraded: Wall Street's top analyst calls (The Fly)
07:45AM	Here Are Wednesday's Top Wall Street Analyst Research Calls: CrowdStrike, Harley-Davidson, Intuitive Surgical, Medline, Nike, Oracle, Planet Fitness, Vici Properties, and More (24/7 Wall St.)
06:11AM	Ligand initiated with a Buy at BofA (TipRanks)
Mar-10-26 05:14PM	IBD Stock Of The Day: Ligand Pharma, Biotech's Royalty Arm, Breaks Out (Investor's Business Daily)
Mar-06-26 12:47PM	This Pharma Stock Shows Strength, Eyes Entry As Earnings Surge 59% (Investor's Business Daily)
09:12AM	These Are The 5 Best Stocks To Buy Or Watch Now (Investor's Business Daily)
Mar-04-26 07:00AM	Ligand to Participate in March Investor Conferences (GlobeNewswire)
Feb-26-26 05:03PM	Ligand Pharmaceuticals Q4 Earnings Call Highlights (MarketBeat)
04:10PM	Ligand Pharmaceuticals Inc (LGND) Q4 2025 Earnings Call Highlights: Surpassing Expectations and ... (GuruFocus.com)
07:50AM	Ligand: Q4 Earnings Snapshot (Associated Press Finance)
07:00AM	Ligand Reports Fourth Quarter and Full Year 2025 Financial Results (GlobeNewswire)
Feb-23-26 04:10PM	Gilead Bets Big On New Drug With $7.8 Billion Deal As It Takes On J&J (Investor's Business Daily)
08:44AM	Gilead Bets Big On Anito-Cel With $7.8 Billion Arcellx Deal (Investor's Business Daily)
Feb-12-26 07:00AM	Ligand to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026 (GlobeNewswire)
Feb-04-26 07:00AM	Ligand to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference (GlobeNewswire)
Jan-30-26 12:39PM	This Pharma Stock Eyes Entries, Battles For Key Level Amid 68% Earnings Growth (Investor's Business Daily)
Jan-13-26 04:36PM	Travere, Ligand Hammered On A Surprise Delay For Their Linchpin Drug (Investor's Business Daily) -8.72%
Jan-12-26 10:32AM	Gamble on Huge Gains with These 3 Best Biotech Stocks to Buy for 2026 (Barchart)
Jan-08-26 07:13AM	Dow Jones Futures Fall; Lockheed, Defense Giants Bounce On $1.5 Trillion Trump 'Dream Military' (Investor's Business Daily)
Jan-07-26 05:05PM	Dow Jones Futures: Stock Market Fades From Highs; Eli Lilly, Google Lead New Buys (Investor's Business Daily)
Dec-09-25 07:00AM	Ligand Hosts 2025 Investor Day and Introduces 2026 Guidance (GlobeNewswire)
Nov-20-25 01:34PM	Why Ligand Pharma, A Hidden Name Behind Two Big Drugs, Is Up 92% This Year (Investor's Business Daily)
Nov-19-25 08:11AM	What Makes Ligand Pharmaceuticals (LGND) an Investment Choice? (Insider Monkey)
Nov-18-25 08:03AM	Why Ligand Pharma, A Hidden Name Behind Two Big Drugs, Is Up 88% This Year (Investor's Business Daily)
Nov-10-25 05:31AM	Pelthos acquires US rights to Xepi cream from Biofrontera and Ferrer (Pharmaceutical Technology)
Nov-06-25 07:14AM	Ligand: Q3 Earnings Snapshot (Associated Press Finance) +9.37%
07:00AM	Ligand Reports Third Quarter 2025 Financial Results and Raises Guidance (GlobeNewswire)
Oct-30-25 04:01PM	Ligand to Participate in November Investor Conferences (GlobeNewswire)
Oct-23-25 07:00AM	Ligand to Report Third Quarter 2025 Financial Results on November 6, 2025 (GlobeNewswire)
Oct-16-25 07:00AM	Ligand to Host Investor Day on December 9, 2025 (GlobeNewswire)
Oct-09-25 07:00AM	Ligand Partner SQ Innovation Receives FDA Approval for Lasix ONYU, an At-Home Treatment for Edema in Heart Failure Patients (GlobeNewswire)
Aug-19-25 04:00PM	Ligand to Participate in September Investor Conferences (GlobeNewswire)
Aug-14-25 04:00PM	Ligand Announces Closing of Convertible Senior Notes Offering (GlobeNewswire)
Aug-12-25 08:14AM	Orchestra BioMed Reports Second Quarter 2025 Financial Results and Highlights Recent Business Updates (GlobeNewswire)
Aug-11-25 11:46PM	Ligand Announces Pricing of $400 Million Convertible Senior Notes Offering (GlobeNewswire)
07:00AM	Ligand Announces Proposed Offering of $400 Million of Convertible Senior Notes Due 2030 (GlobeNewswire)
Aug-07-25 07:24AM	Ligand: Q2 Earnings Snapshot (Associated Press Finance)
07:00AM	Ligand Reports Second Quarter 2025 Financial Results and Raises Guidance (GlobeNewswire)
Aug-05-25 07:00AM	Orchestra BioMed Secures Over $111 Million in Proceeds and Committed Capital Following Completion of Strategic Transactions and Concurrent Public and Private Equity Offerings (GlobeNewswire)
Jul-31-25 04:01PM	Ligand and Medtronic Commit $70 Million in Strategic Capital to Orchestra BioMed (GlobeNewswire)
Jul-24-25 07:00AM	Ligand to Report Second Quarter 2025 Financial Results on August 7, 2025 (GlobeNewswire)
Jul-17-25 02:10PM	Ligand Pharmaceuticals Stock Earns 84 RS Rating (Investor's Business Daily) +6.13%
Jul-12-25 02:00PM	Top 3 small-cap stock picks while navigating trade uncertainty (Yahoo Finance Video)
Jul-10-25 10:43AM	LGND Raises $9M to Make Earth Data Intuitive and Actionable (PR Newswire)
09:58AM	LGND wants to make ChatGPT for the Earth (TechCrunch)
08:00AM	Ligand Partner Pelthos Therapeutics Launches ZELSUVMI (GlobeNewswire)
Jul-03-25 07:17AM	Ligands LNHC concludes merger with CHRO (Pharmaceutical Technology)
Jul-02-25 07:00AM	Pelthos Therapeutics Completes Merger with Channel Therapeutics and Closes $50.1 Million Private Placement (GlobeNewswire)
07:00AM	Ligand Announces Completion of Pelthos Therapeutics Merger with Channel Therapeutics (GlobeNewswire)
Jun-11-25 07:00AM	Ligand Announces 2025 Investor Day in New York City (GlobeNewswire)
May-14-25 07:00AM	Ligand to Ring the Nasdaq Opening Bell on May 19, 2025 (GlobeNewswire)
May-08-25 07:44AM	Ligand Pharmaceuticals Reiterates FY25 Outlook - Update (RTT News)
07:00AM	Ligand Reports First Quarter 2025 Financial Results (GlobeNewswire)
May-07-25 06:00PM	Here are the major earnings before the open tomorrow (Seeking Alpha)
12:09PM	Ligand Pharmaceuticals Q1 2025 Earnings Preview (Seeking Alpha)
May-01-25 07:00AM	Ligand to Participate in May Investor Conferences (GlobeNewswire)
Apr-24-25 07:00AM	Ligand to Report First Quarter 2025 Financial Results on May 8, 2025 (GlobeNewswire)
Apr-20-25 09:35AM	Revisiting Ligand Pharmaceuticals, Ready To Accumulate If Shares Dip Below $100 (Seeking Alpha)
Apr-17-25 06:00AM	Ligand Subsidiary Pelthos Therapeutics to Combine with Channel Therapeutics (GlobeNewswire)
Apr-03-25 11:50AM	Bumbershoot Holdings 2024 Investor Letter (Seeking Alpha) -5.17%
Mar-31-25 04:03PM	Impax Small Cap Fund Q4 2024 Commentary (Seeking Alpha)
07:30AM	Palvella Therapeutics Reports Full Year 2024 Financial Results and Provides Corporate Update (GlobeNewswire)

Show Previous News

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Aryeh Jason	Director	Nov 10 '26	Sale	320.05	3,000	960,141	105,476	Nov 12 04:49 PM
MARTINE ZIMMERMANN	Director	Nov 12 '26	Proposed Sale	318.17	2,000	636,336		Nov 12 04:23 PM
KOZARICH JOHN W	Director	Nov 12 '26	Proposed Sale	325.00	500	162,500		Nov 12 04:04 PM
KOZARICH JOHN W	Director	Nov 11 '26	Proposed Sale	317.32	500	158,659		Nov 12 09:10 AM
Aryeh Jason	Director	Nov 10 '26	Proposed Sale	320.03	3,000	960,084		Nov 10 02:25 PM
Aryeh Jason	Director	Nov 04 '26	Sale	319.99	282	90,237	108,476	Nov 06 05:41 PM
Aryeh Jason	Director	Nov 04 '26	Proposed Sale	319.95	282	90,226		Nov 04 04:42 PM
Reardon Andrew	CLO & Secretary	Nov 02 '26	Option Exercise	52.27	5,000	261,350	36,854	Nov 04 04:23 PM
Reardon Andrew	CLO & Secretary	Nov 02 '26	Sale	313.22	5,000	1,566,094	31,854	Nov 04 04:23 PM
Aryeh Jason	Director	Oct 30 '26	Sale	320.24	1,411	451,860	109,458	Nov 03 07:39 PM
Aryeh Jason	Director	Nov 02 '26	Sale	320.43	700	224,298	108,758	Nov 03 07:39 PM
Aryeh Jason	Director	Nov 02 '26	Proposed Sale	316.56	700	221,595		Nov 02 04:26 PM
JASON M ARYEH	Director	Oct 30 '26	Proposed Sale	318.60	1,209	385,185		Oct 30 04:37 PM
Aryeh Jason	Director	Oct 30 '26	Proposed Sale	320.49	202	64,738		Oct 30 03:38 PM
Reardon Andrew	CLO & Secretary	Oct 02 '26	Option Exercise	52.27	340	17,772	36,854	Oct 06 04:35 PM
Reardon Andrew	CLO & Secretary	Oct 02 '26	Sale	304.07	5,000	1,520,346	31,854	Oct 06 04:35 PM
Zimmermann Martine	Director	Sep 10 '26	Sale	285.00	1,200	342,000	3,897	Sep 14 04:59 PM
MARTINE ZIMMERMANN	Director	Sep 10 '26	Proposed Sale	285.00	1,200	342,000		Sep 10 04:01 PM
Reardon Andrew	CLO & Secretary	Sep 03 '26	Sale	286.09	5,000	1,430,434	36,514	Sep 08 06:34 PM
ANDREW REARDON	Officer	Sep 03 '26	Proposed Sale	286.92	15,000	4,303,800		Sep 03 04:40 PM
Espinoza Octavio	Chief Financial Officer	Aug 12 '26	Option Exercise	56.91	31,641	1,800,574	59,337	Aug 14 05:05 PM
Espinoza Octavio	Chief Financial Officer	Aug 12 '26	Sale	292.06	31,641	9,241,229	27,696	Aug 14 05:05 PM
Haas Jason	Director	Aug 12 '26	Option Exercise	51.56	6,138	316,475	11,119	Aug 14 05:04 PM
Haas Jason	Director	Aug 12 '26	Sale	292.81	7,138	2,090,062	3,981	Aug 14 05:04 PM
OCTAVIO ESPINOZA	Officer	Aug 12 '26	Proposed Sale	288.75	31,641	9,136,339		Aug 12 04:33 PM
Jason Haas	Director	Aug 12 '26	Proposed Sale	292.81	7,138	2,090,062		Aug 12 04:23 PM
Reardon Andrew	CLO & Secretary	Aug 03 '26	Option Exercise	52.27	5,000	261,350	46,514	Aug 04 06:42 PM
Reardon Andrew	CLO & Secretary	Aug 03 '26	Sale	288.99	5,000	1,444,951	41,514	Aug 04 06:42 PM
Reardon Andrew	CLO & Secretary	Jul 01 '26	Option Exercise	52.27	5,000	261,350	46,514	Jul 06 05:11 PM
Reardon Andrew	CLO & Secretary	Jul 01 '26	Sale	313.28	5,000	1,566,377	41,514	Jul 06 05:11 PM
ANDREW REARDON	Officer	Jul 01 '26	Proposed Sale	316.09	10,000	3,160,900		Jul 01 04:57 PM
Sabba Stephen L	Director	Jun 16 '26	Option Exercise	66.13	2,145	141,849	35,774	Jun 18 08:37 AM
Sabba Stephen L	Director	Jun 16 '26	Sale	254.00	2,145	544,830	33,629	Jun 18 08:37 AM
STEPHEN L. SABBA	Director	Jun 16 '26	Proposed Sale	254.00	2,145	544,830		Jun 16 04:30 PM
Haas Jason	Director	Jun 12 '26	Option Exercise	51.56	4,000	206,240	11,442	Jun 15 09:06 PM
Haas Jason	Director	Jun 12 '26	Sale	255.58	6,461	1,651,320	4,981	Jun 15 09:06 PM
Aryeh Jason	Director	Jun 11 '26	Sale	250.00	4,500	1,125,000	102,580	Jun 12 05:27 PM
Aryeh Jason	Director	Jun 10 '26	Sale	250.00	500	125,000	107,080	Jun 12 05:27 PM
LAMATTINA JOHN L	Director	Jun 10 '26	Sale	250.88	4,591	1,151,774	26,969	Jun 12 05:26 PM
JASON HAAS	Director	Jun 12 '26	Proposed Sale	256.00	6,461	1,654,016		Jun 12 04:09 PM
Aryeh Jason	Director	Jun 11 '26	Proposed Sale	249.97	4,500	1,124,880		Jun 11 12:21 PM
Aryeh Jason	Director	Jun 10 '26	Proposed Sale	249.96	500	124,980		Jun 10 04:45 PM
JOHN L LAMATTINA	Director	Jun 10 '26	Proposed Sale	250.88	4,519	1,133,711		Jun 10 04:07 PM
Aryeh Jason	Director	Jun 10 '26	Proposed Sale	249.35	5,000	1,246,750		Jun 10 01:41 PM
Reardon Andrew	CLO & Secretary	Jun 01 '26	Option Exercise	52.27	5,000	261,350	46,382	Jun 02 06:22 PM
Reardon Andrew	CLO & Secretary	Jun 01 '26	Sale	227.06	5,000	1,135,316	41,382	Jun 02 06:22 PM
Espinoza Octavio	Chief Financial Officer	May 27 '26	Option Exercise	57.58	1,736	99,966	27,679	May 28 07:43 PM
KOZARICH JOHN W	Director	May 13 '26	Option Exercise	69.51	1,575	109,478	43,361	May 14 09:08 PM
KOZARICH JOHN W	Director	May 12 '26	Option Exercise	69.51	459	31,905	42,245	May 14 09:08 PM
KOZARICH JOHN W	Director	May 13 '26	Sale	223.50	1,575	352,012	41,786	May 14 09:08 PM
KOZARICH JOHN W	Director	May 01 '26	Sale	231.80	467	108,251	41,786	May 14 09:08 PM
KOZARICH JOHN W	Director	May 12 '26	Sale	224.00	459	102,816	41,786	May 14 09:08 PM
JOHN KOZARICH	Director	May 13 '26	Proposed Sale	223.50	1,575	352,012		May 13 04:09 PM
JOHN KOZARICH	Director	May 12 '26	Proposed Sale	224.00	459	102,816		May 12 05:45 PM
Reardon Andrew	CLO & Secretary	May 01 '26	Option Exercise	52.27	5,000	261,350	46,382	May 04 08:20 PM
Reardon Andrew	CLO & Secretary	May 01 '26	Sale	231.31	5,000	1,156,556	41,382	May 04 08:20 PM
KOZARICH JOHN W	Director	May 01 '26	Proposed Sale	229.87	467	107,349		May 01 04:16 PM
KOZARICH JOHN W	Director	Apr 01 '26	Sale	202.23	467	94,440	42,253	Apr 02 07:43 PM
Reardon Andrew	CLO & Secretary	Apr 01 '26	Option Exercise	52.27	5,000	261,350	46,382	Apr 02 06:56 PM
Reardon Andrew	CLO & Secretary	Apr 01 '26	Sale	201.24	5,000	1,006,224	41,382	Apr 02 06:56 PM
KOZARICH JOHN W	Director	Apr 01 '26	Proposed Sale	203.50	467	95,034		Apr 01 04:10 PM
LAMATTINA JOHN L	Director	Mar 06 '26	Option Exercise	114.15	2,161	246,678	32,885	Mar 31 05:53 PM
LAMATTINA JOHN L	Director	Mar 06 '26	Sale	200.76	2,161	433,842	30,724	Mar 31 05:53 PM
Sabba Stephen L	Director	Mar 23 '26	Sale	207.87	1,000	207,873	32,793	Mar 25 11:13 AM
STEPHEN L. SABBA	Director	Mar 23 '26	Proposed Sale	207.87	1,000	207,873		Mar 23 04:04 PM
Espinoza Octavio	Chief Financial Officer	Mar 11 '26	Option Exercise	92.65	2,405	222,823	24,067	Mar 13 07:29 PM
Espinoza Octavio	Chief Financial Officer	Mar 11 '26	Sale	225.00	3,057	687,825	21,010	Mar 13 07:29 PM
OCTAVIO ESPINOZA	Officer	Mar 11 '26	Proposed Sale	212.29	3,057	648,971		Mar 11 04:42 PM
Reardon Andrew	CLO & Secretary	Mar 04 '26	Option Exercise	52.27	5,000	261,350	41,869	Mar 06 06:51 PM
Reardon Andrew	CLO & Secretary	Mar 04 '26	Sale	206.35	5,000	1,031,770	36,869	Mar 06 06:51 PM
Espinoza Octavio	Chief Financial Officer	Mar 04 '26	Option Exercise	63.49	2,073	131,609	35,085	Mar 06 06:49 PM
Espinoza Octavio	Chief Financial Officer	Mar 04 '26	Sale	205.83	13,423	2,762,822	21,662	Mar 06 06:49 PM
JOHN L LAMATTINA	Director	Mar 06 '26	Proposed Sale	200.76	2,161	433,842		Mar 06 04:17 PM
Sabba Stephen L	Director	Mar 03 '26	Option Exercise	69.51	2,034	141,383	35,827	Mar 05 11:05 AM
Sabba Stephen L	Director	Mar 03 '26	Sale	201.50	2,034	409,851	33,793	Mar 05 11:05 AM
KOZARICH JOHN W	Director	Mar 02 '26	Sale	200.50	467	93,632	42,720	Mar 04 09:04 PM
ANDREW REARDON	Officer	Mar 04 '26	Proposed Sale	204.24	20,000	4,084,800		Mar 04 04:44 PM
OCTAVIO ESPINOZA	Officer	Mar 04 '26	Proposed Sale	204.24	13,423	2,741,514		Mar 04 04:39 PM
STEPHEN L. SABBA	Director	Mar 03 '26	Proposed Sale	201.50	2,034	409,851		Mar 03 04:27 PM
KOZARICH JOHN W	Director	Feb 02 '26	Sale	195.91	467	91,490	43,187	Feb 04 05:18 PM
KOZARICH JOHN W	Director	Feb 02 '26	Proposed Sale	192.18	467	89,748		Feb 02 04:12 PM
KOZARICH JOHN W	Director	Jan 02 '26	Sale	189.58	467	88,532	43,654	Jan 06 07:47 PM
KOZARICH JOHN W	Director	Jan 02 '26	Proposed Sale	188.60	467	88,076		Jan 02 04:04 PM
Espinoza Octavio	Chief Financial Officer	Dec 16 '25	Option Exercise	69.00	2,381	164,298	28,567	Dec 18 04:19 PM
Espinoza Octavio	Chief Financial Officer	Dec 12 '25	Sale	188.31	1,804	339,711	26,186	Dec 16 06:36 PM
OCTAVIO ESPINOZA	Officer	Dec 12 '25	Proposed Sale	188.31	1,804	339,711		Dec 12 05:22 PM
Aryeh Jason	Director	Dec 08 '25	Option Exercise	69.51	2,034	141,383	71,323	Dec 08 07:38 PM
KOZARICH JOHN W	Director	Dec 01 '25	Sale	195.84	467	91,457	44,121	Dec 03 05:08 PM
KOZARICH JOHN W	Director	Dec 01 '25	Proposed Sale	199.88	467	93,344		Dec 01 04:08 PM

Ligand Pharmaceuticals, Inc. is a biopharmaceutical company that involves clinical development and commercialization of high-value medicines. Its platforms, Captisol and NITRICI, offer technology with broad applicability in drug development to a large network of biopharmaceutical partners, including the largest pharmaceutical manufacturers in the world. The company was founded by Ronald M. Evans in 1987 and is headquartered in Jupiter, FL.

CEO & DirectorMr. Todd C. Davis Ph.D.

Chief Financial OfficerMr. Octavio Espinoza

Chief Legal Officer & SecretaryMr. Andrew T. Reardon J.D.

Senior Vice President of Investments & Business DevelopmentMr. Paul J. Hadden

Executive Director of Investor Relations and Financial Planning & AnalysisMs. Melanie J. Herman CPA

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

All the Features.Half the Price.

LGND

Ligand Pharmaceuticals Inc

Upgrade your Finviz experience

All the Features.
Half the Price.